Research progress on risk factors for poor response of ursodeoxycholic acid in primary biliary cholangitis
10.3760/cma.j.issn.1007-3418.2019.01.018
- VernacularTitle: 原发性胆汁性胆管炎熊去氧胆酸治疗应答不佳危险因素的研究进展
- Author:
Zhou YUAN
1
;
Gui JIA
;
Ying HAN
Author Information
1. Department of Digestive Disease, Xijing Hospital, the Military Medical University of Air Force PLA, Xi'an 710032, China
- Publication Type:Review
- Keywords:
Liver cirrhosis, biliary;
Ursodeoxycholic acid;
Response
- From:
Chinese Journal of Hepatology
2019;27(1):73-76
- CountryChina
- Language:Chinese
-
Abstract:
Primary biliary cholangitis (PBC) is an autoimmune-mediated chronic cholestatic liver disease. Ursodeoxycholic acid (UDCA) is a first-line drug approved by the Food and Drug Administration for the treatment of PBC. It can effectively improve serum biochemical indicators, delay histological progress, and prolong the survival of non-transplant patients. However, around 40% of patients with PBC have a poor response to UDCA with a poor outcome. Early identification of patients with poor biochemical responses and timely second-line treatment may alter the course of the disease. This article summarizes the risk factors for the poor response of UDCA in the PBC.
